Free Trial
NASDAQ:BCTX

Briacell Therap Q2 2025 Earnings Report

Briacell Therap logo
$3.07 -0.02 (-0.65%)
Closing price 06/9/2026 04:00 PM Eastern
Extended Trading
$3.08 +0.01 (+0.39%)
As of 05:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Briacell Therap EPS Results

Actual EPS
-$23.30
Consensus EPS
-$19.40
Beat/Miss
Missed by -$3.90
One Year Ago EPS
N/A

Briacell Therap Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Briacell Therap Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Briacell Therap Earnings Headlines

Briacell Therap (NASDAQ:BCTX) Shares Up 0.3% - Time to Buy?
BriaCell Therapeutics Announces Closing of Offering
Musk is burning $2.5 billion a quarter on AI. One company holds the key.
SpaceX's S-1 filing reveals $7.7 billion spent on AI infrastructure in a single quarter - not chips, not software, but power infrastructure. The filing shows $23.85 billion in servers and $14 billion in construction in progress, all dependent on one company's hardware. Without this supplier, Colossus doesn't run and the $1.25 billion Anthropic pays monthly stops flowing. The stock is still trading like no one has read the filing - but analyst Dylan Jovine has, and he's releasing the name at no cost.tc pixel
BriaCell Presents Positive Clinical Data at ASCO 2026
BriaCell Therapeutics Announces Pricing of Offering
See More Briacell Therap Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Briacell Therap? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Briacell Therap and other key companies, straight to your email.

About Briacell Therap

Briacell Therap (NASDAQ:BCTX)eutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

View Briacell Therap Profile